Eloralintide common uses, half-life, side effects and more

Eloralintide is a long-acting synthetic version of amylin. Amylin is a hormone the pancreas releases alongside insulin to signal fullness after a meal. Eloralintide is in development as a once-weekly injection for weight loss. It is not approved by any health authority in any country. There is no legitimate prescription supply. People who obtain eloralintide outside a clinical trial use research-grade material of unverified identity, strength, and sterility.

• Weight loss and obesity
• Appetite suppression and early fullness
• Extra weight loss on top of tirzepatide or retatrutide
• Obesity in people with type 2 diabetes

Once weekly

Trials give 1 mg to 9 mg once a week as an injection under the skin. Most phase 2 arms started at their full dose but the arm that began at 3 mg and stepped to 6 mg and then 9 mg at 4-week intervals had the least nausea and vomiting of the arms that reached 6 mg or more. That gentler ladder lost 16.4% at 48 weeks against 20.1% on a fixed 9 mg dose. Community users report 1 mg to 4 mg once a week and often add it to tirzepatide or retatrutide. Their starting doses and steps vary and follow no shared schedule.

• The trials told people to take a missed dose as soon as possible unless the next dose was less than 72 hours away

A published trial puts the half-life of eloralintide at 310 to 366 hours in people, which is about 13 to 15 days. That is why it is injected once a week. Blood levels peak three to four days after each injection and settle after about twelve weeks of weekly doses.

Trial eloralintide came as a ready-to-inject liquid. No trial describes how to reconstitute the powder sold gray-market. The developer's animal studies dissolved eloralintide in a buffer at pH 8 and dissolved cagrilintide at pH 4. Many cagrilintide users reconstitute with acetic acid water to keep the solution acidic. Nothing supports doing the same with eloralintide.

• Nausea is most common in the first weeks and reached 25% to 64% on 6 mg or more against 13% on placebo
• Fatigue affected 21% to 46% of people on 6 mg or more against 12% on placebo
• Diarrhea and vomiting reached 36% and 25% on a fixed 6 mg dose against 10% and none on placebo
• Constipation reached 24% on 9 mg against 6% on placebo
• Hair loss affected 7% of people against none on placebo
• Slow heart rate affected 4% to 6% of people and rarely caused symptoms

Eloralintide is a modified form of human amylin with 37 amino acids. Human cell tests show it activates amylin receptor 1 at about one twelfth the concentration it needs at the calcitonin receptor. It activates amylin receptor 3 and the calcitonin receptor about equally. It still fully activates all three at high enough levels. A C20 fatty diacid chain binds albumin in the blood and stretches dosing out to once weekly. The developers propose that its preference for amylin receptor 1, its slow absorption, its long half-life, or a mix of these makes it easier to tolerate than other amylin drugs. No trial has compared it with another amylin drug. There is no settled account of how the weight loss happens in people. No human study has located where in the brain it acts. A 12-week study measured stomach emptying indirectly and found a mild slowing after the first dose at 6 mg and 12 mg that was gone by week 12.

The human evidence is early and all of it comes from the developer. Three published studies cover 48 healthy adults given a single dose, 100 adults with obesity or overweight dosed for 12 weeks, and 263 adults without diabetes dosed for 48 weeks. The 48-week trial estimated weight loss of 9.5% on 1 mg and 20.1% on 9 mg for people who stayed on treatment against 0.4% on placebo. A 367-person diabetes trial and two small tirzepatide combination studies appear only in a press release and conference talks. Five phase 3 trials planned for about 5,600 people began between December 2025 and February 2026. No animal study of reproduction or cancer has been published and neither have anti-drug antibody results. Mood problems made 3 of 36 people on 12 mg stop the 12-week study but the 48-week trial found no more depression than placebo. Some public dosing pages attribute the 64% nausea rate to the 9 mg dose when it belongs to the arm that stayed on 6 mg from the first dose.

• Eloralintide is not for use in pregnancy or breastfeeding and trials required birth control for about 3.5 months after the last dose in women and 5.5 months in men
• Gray-market eloralintide is unapproved and can vary in purity, dose accuracy, and sterility
• Stomach side effects were more frequent when it was added to tirzepatide and no study has tested it with retatrutide
• Eloralintide can slow the heart and people with a resting pulse below 60 or a history of slow heart rhythm were kept out of the trials
• Combining it with insulin or a sulfonylurea has no published safety data while the related drug pramlintide carries a boxed warning for severe low blood sugar with insulin
• Lasting vomiting or diarrhea can cause dehydration severe enough to injure the kidneys